Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

785 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O'Sullivan J, Fox S, Ailts I, Dueck AC, Geyer HL, Mesa RA, Dunn WG, Nadezhdin E, Curto-Garcia N, Green A, Wilkins B, Coppell J, Laurie J, Garg M, Ewing J, Knapper S, Crowe J, Chen F, Koutsavlis I, Godfrey A, Arami S, Drummond M, Byrne J, Clark F, Mead-Harvey C, Baxter EJ, McMullin MF, Mead AJ. Harrison CN, et al. Among authors: yap c. J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1. J Clin Oncol. 2023. PMID: 37126762 Free PMC article. Clinical Trial.
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF. Harrison CN, et al. Among authors: yap c. Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9. Blood. 2017. PMID: 29074595 Free PMC article. Clinical Trial.
De-Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent myelodysplastic syndromes.
Killick S, Jackson A, Coulthard HC, Yap C, Das-Gupta E, Pennell DJ, Porter J, Bowen D, Culligan D. Killick S, et al. Among authors: yap c. Br J Haematol. 2020 Jun;189(6):e237-e240. doi: 10.1111/bjh.16669. Epub 2020 Apr 27. Br J Haematol. 2020. PMID: 32342485 Free article. Clinical Trial. No abstract available.
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
Craddock C, Slade D, De Santo C, Wheat R, Ferguson P, Hodgkinson A, Brock K, Cavenagh J, Ingram W, Dennis M, Malladi R, Siddique S, Mussai F, Yap C. Craddock C, et al. Among authors: yap c. J Clin Oncol. 2019 Mar 1;37(7):580-588. doi: 10.1200/JCO.18.00889. Epub 2019 Jan 17. J Clin Oncol. 2019. PMID: 30653424 Free PMC article. Clinical Trial.
Discarded livers tested by normothermic machine perfusion in the VITTAL trial: Secondary end points and 5-year outcomes.
Mergental H, Laing RW, Kirkham AJ, Clarke G, Boteon YL, Barton D, Neil DAH, Isaac JR, Roberts KJ, Abradelo M, Schlegel A, Dasari BVM, Ferguson JW, Cilliers H, Morris C, Friend PJ, Yap C, Afford SC, Perera MTPR, Mirza DF. Mergental H, et al. Among authors: yap c. Liver Transpl. 2024 Jan 1;30(1):30-45. doi: 10.1097/LVT.0000000000000270. Epub 2023 Dec 15. Liver Transpl. 2024. PMID: 38109282 Clinical Trial.
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.
Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, Vyas P, Goodyear O, Tholouli E, Crawley C, Russell N, Byrne J, Malladi R, Snowden J, Dennis M. Craddock C, et al. Among authors: yap c. Biol Blood Marrow Transplant. 2016 Feb;22(2):385-390. doi: 10.1016/j.bbmt.2015.09.004. Epub 2015 Sep 9. Biol Blood Marrow Transplant. 2016. PMID: 26363443 Free PMC article.
Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial.
Newsome PN, Fox R, King AL, Barton D, Than NN, Moore J, Corbett C, Townsend S, Thomas J, Guo K, Hull D, Beard HA, Thompson J, Atkinson A, Bienek C, McGowan N, Guha N, Campbell J, Hollyman D, Stocken D, Yap C, Forbes SJ. Newsome PN, et al. Among authors: yap c. Lancet Gastroenterol Hepatol. 2018 Jan;3(1):25-36. doi: 10.1016/S2468-1253(17)30326-6. Epub 2017 Nov 7. Lancet Gastroenterol Hepatol. 2018. PMID: 29127060 Free PMC article. Clinical Trial.
785 results